Cardiovascular health of patients with cancer and cancer survivors: A roadmap to the next level

Journal of the American College of Cardiology

Volumn 65, Issue 25, 2015, Pages 2739-2746

  Barac, Ana ^a   Murtagh, Gillian ^b   Carver, Joseph R ^c   Chen, Ming Hui ^d   Freeman, Andrew M ^e   Herrmann, Joerg ^f   Iliescu, Cezar ^g   Ky, Bonnie ^h   Mayer, Erica L ^d   Okwuosa, Tochi M ⁱ   Plana, Juan Carlos ^j   Ryan, Thomas D ^k   Rzeszut, Anne K ^l   Douglas, Pamela S ^m  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e DEPARTMENT OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^l AMERICAN COLLEGE OF CARDIOLOGY   (United States)

^m DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

cancer survivorship; cardio oncology; cardiovascular risk prevention; cardiovascular toxicity

Indexed keywords

ATTITUDE TO HEALTH; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVOR; CARDIO ONCOLOGY; CLINICAL PRACTICE; FUNDING; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE SURVEY; HEALTH PROGRAM; HUMAN; MEDICAL EDUCATION; MEDICAL SPECIALIST; ONCOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED STATES; CARDIOLOGY; CARDIOVASCULAR DISEASES; COMPLICATION; INFORMATION PROCESSING; NEOPLASMS; SURVIVOR; TRENDS;

CARDIOLOGY; CARDIOVASCULAR DISEASES; DATA COLLECTION; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; SURVIVORS;

EID: 84937467832     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.04.059     Document Type: Review

References (44)

1. A. Albini, G. Pennesi, F. Donatelli, and et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention J Natl Cancer Inst 102 2010 14 25
2. G. Minotti, E. Salvatorelli, and P. Menna Pharmacological foundations of cardio-oncology J Pharmacol Exp Ther 334 2010 2 8
3. E.T. Yeh Onco-cardiology: the time has come Tex Heart Inst J 38 2011 246 247
4. M.S. Ewer, M.K. Ali, B. Mackay, and et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin J Clin Oncol 2 1984 112 117
5. M.S. Ewer, D.D. Von Hoff, and R.S. Benjamin A historical perspective of anthracycline cardiotoxicity Heart Fail Clin 7 2011 363 372
6. E.A. Lefrak, J. Pitha, S. Rosenheim, and et al. A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 32 1973 302 314
7. D.D. Von Hoff, M.W. Layard, P. Basa, and et al. Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
8. M.S. Ewer, M.T. Vooletich, J.B. Durand, and et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 2005 7820 7826
9. M.G. Khouri, P.S. Douglas, J.R. Mackey, and et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues Circulation 126 2012 2749 2763
10. J.M. Duran, C.A. Makarewich, D. Trappanese, and et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction Circ Res 114 2014 1700 1712
11. S.M. Jay, A.C. Murthy, J.F. Hawkins, and et al. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential Circulation 128 2013 152 161
12. S. Zhang, X. Liu, T. Bawa-Khalfe, and et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 18 2012 1639 1642
13. D. Cardinale, M.T. Sandri, A. Colombo, and et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754
14. D. Cardinale, A. Colombo, R. Torrisi, and et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
15. J.H. Jordan, R.B. D'Agostino Jr., C.A. Hamilton, and et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance Circ Cardiovasc Imaging 7 2014 872 879
16. B. Ky, M. Putt, H. Sawaya, and et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab J Am Coll Cardiol 63 2014 809 816
17. H. Sawaya, I.A. Sebag, J.C. Plana, and et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab Circ Cardiovasc Imaging 5 2012 596 603
18. P. Thavendiranathan, F. Poulin, K.D. Lim, and et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review J Am Coll Cardiol 63 2014 2751 2768
19. X. Bosch, M. Rovira, M. Sitges, and et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies) J Am Coll Cardiol 61 2013 2355 2362
20. D. Cardinale, A. Colombo, M.T. Sandri, and et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481
21. N. Kalay, E. Basar, I. Ozdogru, and et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262
22. S. Seicean, A. Seicean, J.C. Plana, and et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study J Am Coll Cardiol 60 2012 2384 2390
23. E.J. Bowles, R. Wellman, H.S. Feigelson for the Pharmacovigilance Study Team Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study J Natl Cancer Inst 104 2012 1293 1305
24. S.C. Darby, M. Ewertz, P. McGale, and et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer N Engl J Med 368 2013 987 998
25. G. Ezaz, J.B. Long, C.P. Gross, and et al. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer J Am Heart Assoc 3 2014 e000472
26. H.T. Tsai, C. Isaacs, A.Z. Fu, and et al. Risk of cardiovascular adverse events from trastuzumab (Herceptin) in elderly persons with breast cancer: a population-based study Breast Cancer Res Treat 144 2014 163 170
27. M.H. Chen, S.D. Colan, and L. Diller Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers Circ Res 108 2011 619 628
28. T. Force, and R. Kerkela Cardiotoxicity of the new cancer therapeutics - mechanisms of, and approaches to, the problem Drug Discov Today 13 2008 778 784
29. B. Ky, P. Vejpongsa, E.T. Yeh, and et al. Emerging paradigms in cardiomyopathies associated with cancer therapies Circ Res 113 2013 754 764
30. H. Lal, K.L. Kolaja, and T. Force Cancer genetics and the cardiotoxicity of the therapeutics J Am Coll Cardiol 61 2013 267 274
31. N. Shelburne, B. Adhikari, J. Brell, and et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities J Natl Cancer Inst 106 2014 dju232
32. P. Vejpongsa, and E.T. Yeh Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities J Am Coll Cardiol 64 2014 938 945
33. E.T. Yeh, and C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231 2247
34. M. Ammon, N. Arenja, G. Leibundgut, and et al. Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice J Card Fail 19 2013 629 634
35. G.J. Yoon, M.L. Telli, D.P. Kao, and et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 56 2010 1644 1650
36. J.L. Halperin, E.S. Williams, V. Fuster, and et al. ACC 2015 core cardiovascular training statement 4 (COCATS 4) (Revision of COCATS 3) J Am Coll Cardiol 65 2015 1721 1723
37. Denlinger CS, Ligibel JA, Are M, et. al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) Survivorship 1.2015. (c) 2015. National Comprehensive Cancer Network, Inc. Available at: www.NCCN.org. Accessed May 4, 2015.
38. P. Lancellotti, V.T. Nkomo, L.P. Badano for the European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance and the American Society of Nuclear Cardiology Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography Eur Heart J Cardiovasc Imaging 14 2013 721 740
39. J.C. Plana, M. Galderisi, A. Barac, and et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging J Am Soc Echocardiogr 27 2014 911 939
40. MD Anderson Cancer Center. Cancer and the heart programs. Available at: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/cardiology/cancer-and-the-heart/index.html. Accessed May 4, 2015.
41. International CardiOncology Society. Available at: http://icosna.org. Accessed May 4, 2015.
42. M.S. Ewer, and E.T. Yeh Cancer and the Heart 2nd edition 2013 People's Medical Publishing House Shelton, CT
43. Makari-Judon G, Mayer EL. 2013 oncology literature reviews breast cancer - fourth quarter. ASCO University. Available at: http://university.asco.org/2013-oncology-literature-reviews-breast-cancer-fourth-quarter. Accessed May 4, 2015.
44. Ruddy K, Moslehi J. Cardiac complications of cancer therapy. ASCO University. Available at: http://university.asco.org/cardiac-complications-cancer-therapy. Accessed May 4, 2015.